cuneo2415d
Alla chiesa di Villar San Costanzo arriva “Nuova Primavera”
Don Carlo Cravero e il sindaco Stefano Ribero danno appuntamento a domenica 16 marzo a partire dalle 14:30 a San Costanzo al Monte per una visita acompagnata al complesso e non solo Domenica 16, a ...
Arte.it20d
Donne nell’arte. A Vienna, per un 2025 al femminile
Mondo - Per secoli il loro contributo allo sviluppo dell’arte è stato sottovalutato o addirittura rimosso, ma per le donne artiste di ogni epoca è arrivato il momento della rivincita. Negli ultimi ...
Arte.it23d
Chiesa di sant'Ivo alla Sapienza
Sulla facciata concava, già esistente, il Borromini aggiunse l'attico, sopra cui si innalza il tiburio polilobato della cupola; gli attacchi tra tiburio e attico sono coperti da tamburi sovrastati ...
BioSpace29d
IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer
She has been in executive roles at multiple biotechnology companies, including Novartis (NIBR), Cardioxyl Pharmaceuticals, Imara Therapeutics, Tiburio Therapeutics and Cydan II, and is currently on ...
WKRN-TV29d
IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer
She has been in executive roles at multiple biotechnology companies, including Novartis (NIBR), Cardioxyl Pharmaceuticals, Imara Therapeutics, Tiburio Therapeutics and Cydan II, and is currently ...
Yahoo Finance29d
IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer
NOTTINGHAM, England, Feb. 25, 2025 /CNW/ -- IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease and ...
Yahoo Finance29d
IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer
NOTTINGHAM, England, Feb. 25, 2025 /CNW/ -- IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease ...